Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system ... BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world. Mehr anzeigen
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), ein globales Onkologieunternehmen, das seinen Namen in BeOne Medicines Ltd. ändern wird, gab heute bekannt, dass es mit CSPC Zhongqi...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), société internationale d’oncologie qui prévoit de changer de nom pour devenir BeOne Medicines Ltd., a annoncé aujourd’hui avoir conclu un...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it has entered into a global licensing...
SEQUOIA試験の5年追跡調査では、BRUKINSAによる治療が、治療未経験のCLL患者における進行または死亡のリスクをベンダムスチン・リツキシマブと比較して71%減少させたことを証明し、最も広範な適応を持つBTK阻害...
SEQUOIA研究的5年隨訪顯示，相較bendamustine-rituximab，BRUKINSA治療在初治CLL病患中將惡化或死亡風險降低了71%，具有最廣泛的BTK抑制劑標籤，從而進一步鞏固了其在一線和復發/難治性(R/R) CLL新病患初治領域...
Aus der 5-Jahres-Nachbeobachtung der SEQUOIA-Studie ging hervor, dass die Behandlung mit BRUKINSA das Risiko von Progression oder Tod bei Patienten mit behandlungsnaiver chronischer...
Le suivi à 5 ans de l’étude SEQUOIA a démontré que le traitement par BRUKINSA réduisait le risque de progression ou de décès de 71 % par rapport à la bendamustine-rituximab chez les patients...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
